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On testing cutaneous T cell lymphoma cell lines and
skin lesions, we found that the transcription factors
STAT2, STAT3, STAT5, and STAT6 (STAT, signal
transducer and activator of transcription) were pre-
sent in the nuclei of these cells and that the binding
to their speci®c DNA binding sites was stimulated by
interleukin-7 and interleukin-15. DNA binding stud-
ies also revealed the presence of three additional
DNA factors in cutaneous T cell lymphoma cells
that bound to the same sequences and could also be
stimulated by interleukin-7 and interleukin-15. One
of these novel factors was also present in the adult T
cell leukemia cell line Jurkat and malignant T cells
from the blood of SeÂzary syndrome patients, but not
in normal peripheral blood lymphocytes. It may
therefore be a marker of T cell leukemia. It seems to
interfere with the binding of STAT1 to the sis indu-
cible element, suggesting that the DNA binding
activity of STAT1 in cutaneous T cell lymphoma
cells is disturbed. Key words: gene regulation/oncogenes/
signal transduction/transcription factors. J Invest Dermatol
117:583±589, 2001
C
utaneous T cell lymphoma (CTCL) is a group of
lymphoproliferative disorders of the skin (Burg et
al, 1997). The most frequent forms of CTCL are
mycosis fungoides (MF) and its leukemic counter-
part the SeÂzary syndrome (SS). MF usually
progresses very slowly (over a period of 5±20 y) but leads
mostly to death by systemic spread of CTCL tumors or
immune disbalance and superinfections. In addition to general-
ized erythroderma, patients with SS also have malignant T cells
in the blood. Their life expectancy is generally shorter (3 y)
than that of patients who suffer from MF. Except in late stages
of disease lymphocyte accumulation in CTCL remains restricted
to the skin. This fact implies that CTCL cells may remain
dependent on growth factors preferentially produced in the skin.
Candidates for such factors are interleukin-7 (IL-7), which is
produced by keratinocytes among other cell types (Dalloul et al,
1992; Matsue et al, 1993), and IL-15, which is expressed in
normal skin (Mohamadzadeh et al, 1995; Blauvelt et al, 1996).
Both IL-7 and IL-15 have been shown to increase the survival
of freshly isolated CTCL cells in vitro (DoÈbbeling et al, 1998).
IL-15 is also produced by CTCL cells in the skin of patients
(DoÈbbeling et al, 1998), and increasing endogenous IL-15
production during tumor progression (Asadullah et al 2000) may
help CTCL cells to become independent of IL-15 produced in
the cutaneous environment.
IL-15 has been identi®ed as a T cell growth stimulating cytokine
produced by many cell types and tissues (Grabstein et al, 1994). The
receptors of IL-2, IL-7, and IL-15 are structurally related: the IL-15
receptor contains the b and g chain of the IL-2 receptor and a
recently identi®ed speci®c a chain (Giri et al, 1994; 1995; Grabstein
et al, 1994). IL-15 could replace IL-2 in several systems (Giri et al,
1994; Grabstein et al, 1994; Armitage et al, 1995), but mostly
proved to be less effective than IL-2. The IL-7 high af®nity
receptor also contains the IL-2 receptor g chain (see Nowak, 1993,
for review).
The IL-2 receptor b and g chains interact with the tyrosine
kinases Janus kinase 1 (Jak1) and Jak3 (Miyazaki et al, 1994; Russell
et al, 1994), which in turn activate the transcription factors STAT3
(signal transducer and activator of transcription 3) and STAT5 (Giri
et al, 1994; Nielsen et al, 1994; Fujii et al, 1995; Wakao et al, 1995).
The STAT family factors bind to DNA elements that mediate the
effects of hormones and growth factors such as prolactin, platelet
derived growth factor, erythropoietin, granulocyte macrophage
colony stimulating factor, and interferons. As the IL-7 and IL-15
receptors contain one or two subunits that are also part of the IL-2
receptor, one may therefore expect that IL-7 and IL-15 may cause
the same effects as IL-2 (Miyazaki et al, 1995). Recent ®ndings do
indeed point in this direction (Johnston et al, 1995; Schindler and
Darnell, 1995). It may also be possible, however, that the recently
identi®ed IL-15 receptor a subunit activates additional STAT
factors.
To study which STAT factors are activated by IL-7 and IL-15
we used the IL-7/IL-15 dependent CTCL cell line SeAx (Kaltoft et
al, 1987) as a test system. These cells are able to survive 4±6 d in the
absence of both cytokines. To determine the effects of IL-7 and IL-
15, the cells were kept for 3 d in the absence of both interleukins
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and after this time the cells were stimulated with IL-7 or IL-15 or
left unstimulated. This system allows us to distinguish the effects of
IL-2, IL-7, and IL-15 and to detect irregularities of interleukin
signal transduction in CTCL cells.
MATERIALS AND METHODS
Cell cultures The cell line HUT 78 (SS) was obtained from the
European Collection of Animal Cell Cultures. The cell lines MyLa 2059
(MF) and SeAx (SS) were kind gifts of Dr. Keld Kaltoft, University of
Aarhus, Denmark. HUT 78, MyLa 2059, and SeÂzary cells from patients
at our department were grown in HEPES-buffered RPMI 1640 medium
with 2 mM glutamine, supplemented with 10% fetal bovine serum
(FBS), 0.25 mg per ml amphotericin B, 100 U penicillin G, 100 U
streptomycin, and 1 mM pyruvate. SeAx cells were grown under the
same conditions with the exception that 10% human serum instead of
10% FBS was used. The concentrations of the cytokines were as follows:
IL-2, 50 ng per ml (100 U); IL-7, 5 ng per ml (10 U); IL-15, 10 ng per
ml (10 U).
Blood and skin samples Skin biopsies and blood samples were taken
primarily for diagnostic purposes with informed consent of the patients.
The specimens used were surplus material available after all the routine
diagnostic procedures. The assignment to a certain stage was done
according to the recommendations of the EORTC Cutaneous
Lymphoma Project Group. SeÂzary cells from patients' blood were
isolated by Ficoll gradient centrifugation and sorted by two-color
¯uorescence-activated cell sorter using antibodies against CD 4 and the
vb region of their T cell receptor (Dummer et al, 1996).
Electrophoretic mobility shift assay (EMSA) and ``supershift''
experiments EMSA were performed according to Barberis et al
(1987). Double stranded g-32P ATP labeled oligonucleotides (30,000
cpm) containing the STAT factor binding motifs of the sis inducible
element (SIE) and the IL-4 responsive element (IL-4RE) were incubated
with 3 mg of nuclear extracts of the investigated cells in binding buffer
consisting of 10 mM HEPES pH 7.9, 60 mM KCl, 4% Ficoll, 1 mM
dithiothreitol, and 1 mM ethylenediamine tetraacetic acid (EDTA)
pH 8.0. Two micrograms of poly[d(I±C)] (poly deoxy-inosinic±deoxy-
citidylic acid) were used as competitor for unspeci®c DNA binding
activities. The total volume of the reaction was 30 ml. In the ``supershift''
experiments, 2±4 mg of the corresponding antibody (Santa Cruz
Biotechnology, TransCruz gel supershift reagent) were added. Nuclear
extracts were prepared according to Gerber et al (1992). The reaction
mixture was incubated for 30 min at 4°C and then loaded on a 4%
native polyacrylamide gel (0.25 3 Tris borate EDTA buffer). The
electrophoresis was run at 4°C for 8±10 h in 0.25 3 TBE buffer at 10 V
per cm. The oligonucleotide sequences for the SIE and IL-4RE were 5¢
GTGCATTTCCCGTAAATCTTGTCTACA 3¢ and 5¢ GAGCCTGA-
TTTCCCCGAAATGATGAGC 3¢, respectively. The oligonucleotides
were synthesized by Microsynth (Balgach, Switzerland).
Western blots For Western blotting 15±30 mg protein of nuclear
extracts or 30±60 mg protein of cytoplasmatic extracts were loaded on a
7.5%±9% sodium dodecyl sulfate polyacrylamide gel and separated by
polyacrylamide gel electrophoresis. The percentage of polyacrylamide
used depended on the molecular weight of the protein to be
investigated. The proteins were transferred to a nitrocellulose ®lter using
a Mini Trans Blot Cell (Bio-Rad) following the instructions of the
supplier. Unspeci®c antibody binding sites were blocked by incubation
of the ®lter overnight at 4°C in Tris-buffered saline (TBS), pH 8.0, 0.3%
Tween 20, and 2% milk powder. The ®lter was incubated with the
corresponding ®rst antibody (Santa Cruz Biotechnology, 1:1000 dilution)
for 4 h at room temperature in TBS, 0.3% Tween 20, and 1% milk
powder. The incubation with the second antibody (antirabbit, Santa
Cruz Biotechnology, 1:1000 dilution) was done in TBS, 0.3% Tween 20
for 4 h at room temperature. The signal was detected by incubation with
BM purple AP substrate (Roche Biochemicals) following the instructions
of the supplier.
RESULTS
IL-7 and IL-15 stimulate the binding of proteins to the
SIE On studying the SIE oligonucleotide for STAT factors in
nuclear extracts from SeAx cells by EMSA we detected two DNA±
protein complexes CS1 and CS2 (CS, complex with SIE), which
were stimulated by IL-2, IL-7, and IL-15 (Fig 1A). The
stimulation occurred within 30 min, indicating that already
present transcription factors were directly activated and that no
protein synthesis was necessary. To determine whether these
Figure 1. Binding of STAT to the SiE. (A) The in¯uence of IL-2
(100 U), IL-7 (10 U), and IL-15 (10 U) on DNA binding activities to
the SIE oligomer in SeAx cells. Lane 1, negative control with peripheral
blood lymphocytes; lanes 2, 3, positive controls with HUT 78 and MyLa
2059 cells; lane 4, no interleukin; lane 5, IL-2 treated SeAx cells; lane 6,
IL-7; lane 7, IL-15. (B) Identi®cation of the SIE binding proteins in
SeAx cells by antibodies against the transcription factors STAT1±STAT6.
Lane 1, negative control with peripheral blood lymphocytes; lane 2,
untreated SeAx cells; lanes 3±9, IL-15 treated SeAx cells. The STAT
proteins were identi®ed by speci®c antibodies against the individual
STAT1±STAT6 proteins (lanes 4±9). The speci®city of the added
antibody is given above the corresponding lane. Only the binding of
STAT3 could be detected (lane 5, CS2). (C) Determination of the
identity of the SIE binding activities in HUT 78 cell line by STAT
antibodies. Lane 1, negative control with peripheral blood lymphocytes;
lanes 2±9, HUT 78 cells. The speci®city of the added antibody is given
above the corresponding lane. Lane 9, competition test with 100 times
excess of unlabeled SIE oligonucleotide (100 3 SIE). (D) SIE binding
activities in MyLa cells. The DNA binding proteins were determined by
antibodies against STAT1±STAT6. Lane 1, negative control with
peripheral blood lymphocytes; lanes 2±8, MyLa cells. The speci®city of
the added antibody is given above the corresponding lane. CSM, MyLa-
speci®c SIE complex; STAT2/5-Ab, STAT2 and STAT5 antibody
complexes.
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complexes contain STAT proteins, we added speci®c antibodies
directed against STAT1±STAT6 to the DNA binding reaction.
The recognition of a DNA binding protein either causes the
disruption of the protein±DNA complex, when the antibody is
directed at the DNA binding domain of the tested protein, or
creates a supershift complex, consisting of the DNA
oligonucleotide, DNA binding protein, and the antibody. These
supershift complexes migrate even more slowly than the DNA±
protein complexes. Testing the complexes in SeAx cells with
antibodies against STAT1±STAT 6, we found that CS2 was
disrupted by an antibody against STAT3, indicating that this
complex contained STAT3 (Fig 1B). CS1 was not signi®cantly
affected by any STAT antibody. In some experiments we found a
slight reduction of CS1 by STAT1 antibodies, but the result was
markedly weaker than the supershift that we obtained with the SIE
and interferon-g stimulated peripheral blood lymphocytes from
normal donors (data not shown). The nuclear extracts from the
HUT 78 and MyLa cell lines also contained CS1 and CS2. CS1 is
probably speci®c for leukemia T cell lines, as it was found in the
acute T cell leukemia cell line Jurkat, but not in hepatoma
(HepG2), breast cancer (MCF-7), or melanoma cells (J.-Z.Q. and
U.D., unpublished data). We therefore called the CS1 forming
factor SBPT (SIE binding protein in T cell lymphoma/leukemia).
Also in HUT 78 and MyLa 2059 cells CS2 was disrupted by a
STAT3 antibody, and CS1 behaved as in SeAx cells (Fig 1C). In
MyLa 2059 cells an additional complex (CSM) was found, which
could be disrupted by antibodies against STAT2 and STAT5
(Fig 1D). In later experiments we found that CSM could also be
visualized when higher amounts of nuclear extracts of HUT 78 and
SeAx were loaded (not shown). The signal of CS2 in MyLa cells
was somewhat reduced by antibodies against STAT4 and STAT5.
As we found no DNA binding of STAT4 on a STAT4-speci®c
oligo (see below), we interpret this signal reduction as a cross-
reaction between STAT3 and STAT4 antibodies. The same
explanation may also be true for the reduction of the CS2 signal
by the STAT5 antibody, as STAT5 is present in the CSM complex.
The presence of low amounts of STAT5 in CS2 cannot be formally
excluded, however. In MyLa 2059 and HUT 78 the stimulating
effect of IL-2, IL-7, and IL-15 was much weaker, which was
probably due to the high basal levels of the SIE binding activities in
these cell lines (data not shown). The complexes below CS2 were
not always reproducible and may be due to sequence-unspeci®c
DNA binding proteins.
IL-7 and IL-15 stimulate the binding of STAT2, STAT5,
and STAT6 to the IL-4 responsive element of the Fcg
receptor I gene (IL-4RE) As not all STAT factors bind to the
same sequence we tested another sequence, which is known to
bind STAT factors: the IL-4RE (Hou et al, 1994). Using the IL-
4RE and nuclear extracts from SeAx cells we found two main
complexes, C-IL-4RE 1 and C-IL-4RE 2. IL-7 and IL-15
increased the DNA binding of both complexes. In normal
peripheral blood lymphocytes (Fig 2B, lane 1) IL-15 induced
another complex, which perhaps is also present in the CTCL cell
lines in low amounts. Supershift experiments with antibodies
against STAT1±STAT6 (Fig 2B) showed that C-IL-4RE 2 was
totally supershifted by an antibody against STAT5 and partially
supershifted by antibodies against STAT2 and STAT6. From this
result one can conclude that C-IL-4RE 2 consists mostly of STAT5
and a lower amount of STAT2 and STAT6. The presence of
several supershift bands suggests that C-IL-4RE 2 consists of
different homodimers and heterodimers of these molecules. C-IL-
4RE 1 showed no supershift with any STAT antibody and only a
weak reduction of the signal was observed when the STAT1
antibody was used. In contrast to the other factors the C-IL-4RE 1
forming factor could also bind to mutated IL-4RE, which lacked
the characteristic thymidine triplet (J.-Z.Q. and U.D., unpublished
data). In HUT 78 and MyLa 2059 cells C-IL-4RE 2 was also
present and reacted with antibodies against STAT2, STAT5, and
STAT6 (Fig 2C, D). Using the so-called IL-4 gamma interferon
activation sequence by which STAT 4 has been identi®ed, we
observed no DNA binding of STAT4, and only a weak interaction
of STAT2, STAT5, and STAT6 with this oligo could be found
(data not shown).
Western blot analysis of STAT factors To see whether the
STAT factors that we found in the supershift experiments were
intact and of the expected size we performed Western blots using
nuclear extracts of the three CTCL cell lines. All the STAT factors
Figure 2. Binding of STAT to the IL-4 responsive element (IL-
4RE) in CTCL cells. (A) IL-7 and IL-15 stimulate the binding of
proteins to the IL-4RE of the Fcg RI gene in SeAx cells. Lane 1, normal
untreated peripheral blood lymphocytes; lane 2, unstimulated SeAx cells;
lanes 3±5, IL-2 (100 U), IL-7 (10 U), IL-15 (10 U) stimulated SeAx
cells. (B) Identi®cation of the proteins binding to the IL-4RE by
antibodies against STAT1±STAT6 in IL-15 stimulated SeAx cells. Lane
1, negative control with IL-15 (10 U) treated peripheral blood
lymphocytes; lanes 2±8, SeAx cells. The speci®city of the added antibody
is given above the corresponding lane. STAT-Ab, STAT±DNA antibody
complexes. (C) Determination of Fcg RI IL-4RE binding activities in
HUT 78 cells. Lane 1, negative control with untreated peripheral blood
lymphocytes; lanes 2±8, SeAx cells. The speci®city of the added antibody
is given above the corresponding lane. (D) Determination of Fcg RI IL-
4RE binding activities in MyLa 2059 cells. Lane 1, negative control with
untreated peripheral blood lymphocytes; lanes 2±8, SeAx cells. The
speci®city of the added antibody is given above the corresponding lane.
Only C-IL-4RE 2, consisting of STAT2, STAT5, and STAT6, could be
detected in HUT 78 and MyLa 2059.
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seen in the supershift experiments (STAT2, STAT3, STAT5,
STAT6) were detected by Western blotting (Fig 3) in all three cell
lines. STAT1 and STAT4, which showed no DNA binding in
EMSA, were also tested and surprisingly STAT1 was detected in all
three nuclear extracts (Fig 3A). When we used the gamma
interferon activating sequence in supershift experiments, however,
a STAT1-speci®c antibody revealed DNA binding of STAT1 to
these sequences (U.D., J.-Z.Q., and C.-L.Z., unpublished data).
The only size difference of STAT proteins in the CTCL cell
lines was seen for STAT2. In HUT 78 and MyLa 2059 cells a
STAT2 form of 105 kDa was prevalent, whereas in SeAx cells a
120 kDa form dominated (Fig 3B). In all the three cell lines
we found the wild-type STAT3 protein. Some preparations of
the K-15 and C-20 antibodies detected proteins of 120±
130 kDa (Fig 3C) and 60 kDa (not shown); however, in
contrast to the STAT3 wt signal these bands were not always
reproducible. No consistent signal for a larger mutant STAT3
protein in MyLa 2059 cells that has been previously reported by
Nielsen et al (1994) was detected, although we used the same
two antibodies.
No signal of the expected size of 88 kDa was detected for STAT4
(Fig 3D). The signals seen in this blot may derive from mutant or
STAT4-related proteins from which only expressed sequence tags
(EST) or partial cDNAs have been cloned. Both STAT5 proteins,
STAT5a and STAT5b, were present in all three cell lines (Fig 3E).
In general, the concentrations of STAT factors were highest in
MyLa 2059 cells and lowest in SeAx cells when equal amounts of
protein were loaded.
In vivo expression and localization of STATs in CTCL skin
lesions When we tested the skin lesions of CTCL patients for the
presence of STAT1, STAT2, STAT3, STAT5, and STAT6, we
found cytoplasmic staining in the malignant T cells of all six MF
and six SS patients tested. The expression and distribution of
STAT1, STAT2, STAT3, and STAT6 were nearly identical and
correspond to the four samples given in Fig 4(A)±(D) for STAT3.
The staining was predominant in the cytoplasm, but nuclear
staining was also detected in skin lesions of all tested CTCL
patients. In one half of the patients we observed signi®cant nuclear
staining in many malignant cells (Fig 4C, D), whereas in the other
half only a few cells showed nuclear staining (Fig 4A, B). There
was no strict correlation between nuclear localization and disease
progression.
All samples tested by a STAT5 antibody showed strong STAT5
staining in the nucleus (Fig 4E±H). Strong nuclear STAT5 staining
was already evident in early stages (Fig 4B, top left) and did not
increase signi®cantly in later stages.
SBPT is present in malignant T cells in the blood of SS
patients As no antibodies against SBPT are available and no
functional nuclear extracts from skin biopsy material can be
prepared, we investigated nuclear extracts of malignant T cells
freshly isolated from the blood of patients with SS for the presence
of SBPT. EMSA showed that a complex migrating at the same
position as CS1 in the CTCL cell lines was present in all seven
patients tested, whereas CS2, which may represent STAT3, was
present in only one patient (Fig 5A). In one patient a very strong
CS1 signal was found ± possibly two different complexes migrating
closely together composed this signal. As in SeAx cells IL-7 and IL-
15 could stimulate the CS1 complex in malignant T cells of patients
(Fig 5B). This complex also did not react signi®cantly with STAT
antibodies. Due to this behavior and the common migration
behavior on the gel we suppose that CS1 is the same in all the tested
samples and represents SBPT. As SBPT is absent in the peripheral
blood lymphocytes of healthy donors we suppose that it is
indicative for CTCL cells in the blood.
When we performed corresponding experiments with the IL-
4RE we found no binding of STATs to this DNA sequence
(J.-Z.Q. and U.D., unpublished data).
DISCUSSION
Our results show that the STAT factors 1, 2, 3, 5, and 6 are
constitutively active in CTCL cell lines and that they can be
stimulated by IL-7 and IL-15 in SeAx cells. This is also true for
the presumed novel factors that bind to the SIE and the IL-
4RE. The ®ve STATs are also present in the nuclei of
malignant T cells in CTCL skin lesions, where STAT5, as in
the cell lines, seems to be the most prominent factor. The
binding of STAT1 to the SIE may be inhibited by the novel
SIE binding factor SBPT.
With respect to constitutive STAT activities, CTCL cells
resemble leukemic cells from acute myeloid leukemia, Burkitt's
lymphoma, and adult T cell leukemia patients (Gouilleux-Gruart et
al, 1996; Weber±Nordt et al, 1996; Takemoto et al, 1997). In
general the unstimulated STAT factor binding is higher in the IL-
7/IL-15 independent cell lines HUT 78 and MyLa 2059 than in the
IL-7/IL-15 dependent SeAx cells. IL-7 and IL-15 increase the
DNA binding of STAT and the novel STAT motifs binding factors
in SeAx cells and thus compensate for the lower constitutive
activity of these factors in this cell line. As SeAx cells survive in the
Figure 3. Expression of STAT1±STAT6 in CTCL cells. (A)
STAT1 expression in HUT 78 (lane 1), MyLa 2059 (lane 2), and SeAx
(lane 3) cells. (B) STAT2 expression in HUT 78 (lane 1), MyLa 2059
(lane 2), and SeAx (lane 3) cells. (C) Expression of STAT3 isoforms in
HUT 78 (lanes 1, 4), MyLa 2059 (lanes 2, 5), and SeAx (lanes 3, 6) cells
tested with antibody K-15 (lanes 1±3) and C-20 (lanes 4±6). (D) STAT4,
(E) STAT5, and (F) STAT6 expression in HUT 78 (lane 1), MyLa 2059
(lane 2), and SeAx (lane 3) cells. The 97.4 kDa band of the protein size
marker is given on the left.
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absence of IL-7 or IL-15 only for 4±6 d, a certain threshold level of
STAT factor activities may be necessary for the survival of these
cells. Due to their high constitutive DNA binding activities, IL-7
and IL-15 increase the DNA binding of STATs in HUT 78 and
MyLa 2059 cells only weakly (data not shown).
Despite the inactivity of STATs, SBPT is also constitutively
present in the nuclei of unstimulated malignant T cells of SS
patients. As the DNA binding activity of this protein is not detected
in the blood of normal donors, it may play a role for the
cancerogenesis of CTCL. SBPT may be typical for leukemia T
cell lines, as it was found in the acute T cell leukemia cell line
Jurkat, but not in peripheral blood lymphocytes of heathy donors.
It was also absent in hepatoma (HepG2), cervix carcinoma (HeLa),
breast cancer (MCF-7), and melanoma cells (J.-Z.Q. and U.D.,
unpublished data).
IL-7 and IL-15 stimulated in SeAx cells a broader range of STAT
and novel STAT motifs binding factors than has been reported for
other cell lines (Schindler and Darnell, 1995; Leonard and O'Shea,
1998). Our results indicate that the speci®city of IL-7 and IL-15
signaling to STAT factors has been lost in CTCL cell lines: even
STAT2, a factor that is selectively induced by interferon-a, was
stimulated by these two interleukins. This loss of speci®city and the
constitutive binding activity of STAT factors cannot be explained
by a constitutive stimulation through the IL-7 and IL-15 regulated
tyrosine kinases Jak1 and Jak3 (Haque et al, 1997) alone, as they
should only stimulate STAT3 and STAT5.
Other tyrosine kinases that have been reported to stimulate
STAT DNA binding, such as c-Src (Yu et al, 1995; Olayioye et al,
1999) or Bmx (Saharinen et al, 1997; Wen et al, 1999), may also be
involved in the constitutive activation of STATs in CTCL cells.
Figure 4. Expression and localization of
STAT proteins in CTCL cells in skin lesions.
(a±d) STAT3 antibody staining experiments with
cryostat sections from skin lesions of two MF
patients (a, c) and two SS patients (b, d). (a) and
(b) represent early stages, (c) and (d) late stages. (e±
h) Corresponding stainings with a STAT5
antibody: (e) early MF stage, (f ) early SS stage, (g)
late MF stage, (h) late SS stage. The
magni®cations are 100x (a±c, f ±h) and 62.5x (d, e).
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The constitutive activities of STATs may be due to the
functional loss of STAT inhibitors. Recently a family of STAT
inhibitors SOCS1±SOCS3 (suppressor of cytokine signaling),
which is involved in a feedback regulation of STAT activation,
has been identi®ed (Endo et al, 1997; Naka et al, 1997; Starr et al,
1997). A failure of these regulators could cause the perpetuation of
a cytokine signal. Indeed, it was found that CTCL cell lines lack
functioning SOCS3 proteins (Brender et al, 2001). The high
concentrations of some STATs, especially STAT5, in the cytoplasm
of CTCL cells in skin lesions suggest that over-expressed STATs
could also titrate STAT inhibitors and that therefore a fraction of
these proteins can migrate into the nucleus.
The Western blots detected the two known forms of STAT2
(p105 and p120). For STAT3 our ®ndings with MyLa 2059 cells
differ from those of Nielsen et al (1997), who detected a slowly
migrating form of STAT3 but no STAT2 and STAT5 binding.
Their ®ndings may be due to the long culture time of this cell line.
STAT3 is constitutively present in all three cell lines and in the
malignant T cells of one patient. The presence of STAT3 in the
malignant T cells of at least one patient suggests that the activation
of STAT3 is a late but normally occurring event during the
progression of CTCL. It may be that SeÂzary cells get the ability to
proliferate in very late stages, as we found expression of the
proliferation-promoting c-myc and junD genes in SeÂzary cells of
patients with very high numbers of leukemic T cells (Qin et al,
1999).
No STAT4 protein of the expected size and DNA binding could
be detected in nuclear extracts of CTCL cells. The absence of this
protein or its inability to become activated may explain why IL-12
induces no STAT4-mediated gene expression in CTCL cells
(Showe et al, 1999). We detected no DNA binding of STAT
proteins in the leukemic T cells of SS patients. Zhang et al (1996)
reported phosphorylated STAT5 proteins in 70% of their SS
patients; however, they did not analyze their DNA binding
activities. Thus it may be possible that STAT5 needs additional
serine phosphorylation for effective binding to the IL-4RE.
CTCL cells are a good source of new IL-7 and IL-15 stimulated
transcription factors as, besides SBPT, we have already discovered
two novel E-box binding proteins in these cells (Qin et al, 1999).
The stimulation of the DNA binding of these factors is speci®c, as it
occurs within less than 30 min and is therefore not due to de novo
protein synthesis; it can occur during a general recovery from
interleukin starvation of the cells after the addition of IL-7 or IL-15.
The speci®city of the effects is also underscored by the fact that the
transcription factors c-Myc, Max, and OCT-1 (Qin et al, 1999) are
not stimulated by these two interleukins. IL-7, IL-15, and the
STATs may play an important role for the survival of CTCL cells,
as we observed that they increased the binding of STAT2, STAT5,
STAT6, and c-Myb to their binding sites in the promoter of the
bcl-2 gene and consequently increased the amount of Bcl-2 protein
in CTCL cells (Qin et al, 2001). CTCL cells may gain IL-7 and IL-
15 independence when signal transduction molecules like tyrosine
kinases mutate to constitutively active enzymes.
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